Allurion Technologies Inc. (ALUR) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a significant revenue decline, despite cost reductions. The Q&A highlights uncertainties in distributor retention and U.S. commercialization, with management providing vague responses. Additionally, the FDA approval timeline remains uncertain, and the competitive landscape is challenging. While there's potential in the combination therapy, the lack of clear guidance and ongoing strategic shifts suggest a cautious outlook, leading to a negative sentiment.
Key Financial Performance
Revenue $3.4 million for Q2 2025, a decrease from $11.8 million in Q2 2024, representing a significant year-over-year decline. The decrease was primarily due to distributor transitions, lower investments in sales and marketing, and the temporary suspension of sales in France.
Gross Profit $2.5 million or 74% of revenue for Q2 2025, compared to $9.0 million or 76% of revenue in Q2 2024. The decline in gross profit was driven by a decrease in sales.
Sales and Marketing Expenses $2.4 million for Q2 2025, down from $6.7 million in Q2 2024, a 64% reduction. This was primarily driven by increased operating efficiency and restructuring initiatives implemented in Q4 2024.
Research and Development Expenses $1.8 million for Q2 2025, compared to $4.3 million in Q2 2024, a 58% reduction. The decrease was primarily due to reduced costs related to the AUDACITY trial and restructuring initiatives implemented in Q4 2024.
General and Administrative Expenses $5.2 million for Q2 2025, down from $7.3 million in Q2 2024, a 29% reduction. This was primarily driven by restructuring initiatives implemented in Q4 2024.
Loss from Operations $7.0 million for Q2 2025, compared to $9.3 million in Q2 2024, a 26% improvement. The reduction was driven by restructuring initiatives implemented in Q4 2024.
Cash and Cash Equivalents $12.7 million as of June 30, 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
GLP-1 drug-eluting intragastric balloon: Signed a term sheet with a strategic partner to expand manufacturing capabilities and explore joint development of a novel GLP-1 drug-eluting intragastric balloon. This innovation aims to address adherence challenges of GLP-1 use and combine two mechanisms of action into a single therapy.
Next-generation Allurion Balloon: Investing in designs to reduce capsule size, increase radiopacity, and introduce new valve technology for longer residence balloons, enhancing long-term weight maintenance.
U.S. market entry: Submitted the fourth and final module of PMA submission to the FDA, aiming for approval to enter the U.S. market. The U.S. obesity market has significant potential with 40% of adults affected and only 8 million currently using injectable obesity therapy.
Distributor transitions: Transitioned away from distribution partners lacking access to metabolically healthy weight loss accounts, finding new partners or converting markets to direct operations. This caused short-term disruptions but is expected to support long-term growth.
Revenue and growth: Revenue for Q2 2025 was $3.4 million, reflecting reduced sales due to distributor transitions but partially offset by growth in direct markets driven by GLP-1 combination therapy. Clinics piloting the combination approach grew by 20% compared to Q1 2025.
Cost efficiency: Operating expenses decreased by 48% year-over-year, driven by restructuring and reorganization efforts. Operating loss improved by 26% compared to the prior year.
Strategic pivot to combination therapy: Shifted focus to combining the Allurion Program with low-dose GLP-1 therapy for metabolically healthy weight loss. This includes targeting accounts promoting comprehensive obesity management and resizing the sales force to focus on high-performing accounts.
Clinical pipeline focus: Prospective multicenter study in Europe to validate combination therapy effects on weight loss, muscle mass, and GLP-1 adherence. Enrollment expected by year-end 2025.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Revenue for Q2 2025 was $3.4 million, a significant decrease from $11.8 million in Q2 2024, primarily due to distributor transitions, reduced sales and marketing investments, and temporary suspension of sales in France.
Distributor Transitions: The company is transitioning away from distribution partners who lack access to accounts and clinicians equipped for metabolically healthy weight loss. This has caused short-term disruptions in sales.
Short-Term Disruption from Strategic Pivot: The pivot to a new strategic direction, including resizing the sales force and focusing on combination therapy, is expected to cause near-term disruptions, impacting revenue and operations.
Regulatory and Approval Risks: The company is awaiting FDA approval for its PMA submission, which is critical for U.S. market entry. Delays or rejections could adversely impact strategic plans.
Economic and Financial Pressures: Operating expenses decreased by 48% year-over-year, but the company still reported a loss from operations of $7.0 million for Q2 2025. Cash and cash equivalents stand at $12.7 million, indicating financial constraints.
Market Competition: GLP-1s are a popular first-line therapy for obesity, and while Allurion aims to address their limitations, the competitive landscape remains challenging.
Supply Chain and Manufacturing Risks: The company signed a term sheet with a strategic partner to expand manufacturing capabilities and distribution. Any delays or issues in this partnership could disrupt operations.
Clinical Validation Risks: The success of the new strategy depends on the validation of combination therapy through clinical trials. Delays or unfavorable results could hinder adoption and market entry.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Future U.S. Market Launch: The company has submitted the fourth and final module of its PMA submission to the FDA, including supportive analyses from the AUDACITY Study. They are working towards FDA approval for a U.S. market launch.
Combination Therapy Strategy: The company is focusing on combining the Allurion Program with low-dose GLP-1 therapy to address adherence challenges and improve metabolically healthy weight loss. This includes a prospective multicenter study in Europe to validate the combination therapy, with enrollment expected to begin by the end of the year.
R&D Pipeline Enhancements: Plans include developing a GLP-1 drug-eluting intragastric balloon and next-generation Allurion Balloons with improved features such as reduced capsule size and longer residence time. These innovations aim to enhance weight loss and muscle mass maintenance.
Global Expansion and Distribution: The company is transitioning to new distribution partners or direct operations in markets where current partners lack access to accounts promoting metabolically healthy weight loss. This is expected to be disruptive in the short term but beneficial for long-term growth.
Revenue Guidance Reevaluation: Due to near-term disruptions from strategic shifts, the company is reevaluating its 2025 revenue guidance.
Cost Alignment Plan: A plan to align operating expenses with the new strategic direction is being implemented, with anticipated charges of approximately $1.5 million in Q3 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How should we think about the cost implications of low-dose GLP-1s combined with the Allurion Gastric Balloon for obesity care in the short, medium, and long term?
A:Internationally, GLP-1s are inexpensive, making the combination therapy with the Allurion Program cost-effective for patients. In the U.S., prices are expected to decrease over time due to market competition and government initiatives, potentially enabling a similar strategy domestically.
Q:What are the cost-effectiveness prospects of the combination therapy with low-dose GLP-1s and the Allurion Balloon?
A:The combination therapy is expected to be cost-effective as it addresses adherence issues, side effects, and muscle mass problems associated with GLP-1s. The Allurion Balloon induces early satiety, while low-dose GLP-1s reduce hunger, leading to sustained weight loss and lower healthcare costs over time.
Q:Can you provide updates on distributor retention and new distributor additions, particularly regarding OUS revenue contributions in 2026?
A:The company is undergoing a strategic shift with distributors in regions like Latin America and the Middle East, which will continue through the second half of the year. This may cause some disruption, but more details will be shared as the process progresses.
Q:What is the expected timeline for FDA approval following the PMA submission?
A:The FDA typically provides feedback within 180 days after the final module submission. Given the modular submission approach and strong data from the AUDACITY Study, the approval timeline might be shorter than the initially estimated 12 months.
Q:What are the expected operating expenses for R&D and G&A in the near term?
A:R&D expenses are expected to remain around $1.8 million for the second half of the year. G&A expenses, currently at $5.2 million, are expected to decrease following the recent restructuring.
Q:What is the current cash runway, especially considering the U.S. launch?
A:The company feels confident about its current cash position in the short term. Future cash needs will depend on the U.S. commercialization strategy and FDA approval timeline.
Q:How will the new combination therapy strategy impact reengagement with accounts in France?
A:The strategy is expected to positively impact reengagement in France. Regulatory changes have expanded GLP-1 access to bariatric surgeons and gastroenterologists, who are interested in using GLP-1s in combination with the Allurion Program due to its benefits over monotherapy.
Q:Review of Unclear Management Responses
A:Management avoided providing specific data on distributor retention percentages and the exact impact of the strategic shift on OUS revenue contributions. Additionally, no concrete details were given on the commercialization strategy for the U.S. market or the exact cash runway duration.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AUDACITY Study
Allurion Program
GLP combination
LLC Research
Program dose
RD
Research Division
analysis
approach obesity
aspect weight
benefit
conference today
control group
difference weight
disruption direction
distribution partner
distributor
drug
endpoint value
focus
fruit
imputation method
issue dos
loss issue
loss treatment
margin endpoint
milligram semaglutide
obesity therapy
pivot
semaglutide month
term success
therapy weight
transition
treatment control
week
ALUR Transcript
Allurion Technologies Inc. (ALUR) Q3 2025 Earnings Call Transcript
Unknown11-12
The company's earnings call reveals several negative factors: a significant revenue decline, restructuring costs, and an operating loss. While there are some positive aspects, like narrowed losses and cost reductions, the overall financial health remains weak. The Q&A section highlights uncertainties in international strategy and product development timelines. Despite optimistic guidance, the combination of competitive pressures, supply chain inefficiencies, and reliance on private financing suggests a likely negative stock price reaction over the next two weeks.
Allurion Technologies Inc. (ALUR) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call reveals a significant revenue decline, despite cost reductions. The Q&A highlights uncertainties in distributor retention and U.S. commercialization, with management providing vague responses. Additionally, the FDA approval timeline remains uncertain, and the competitive landscape is challenging. While there's potential in the combination therapy, the lack of clear guidance and ongoing strategic shifts suggest a cautious outlook, leading to a negative sentiment.
Allurion Technologies Inc. (NYSE:ALUR) Q1 2025 Earnings Call Transcript
Unknown5-15
The earnings call highlights a mixed picture. While there are positive developments like reduced operating expenses, restructuring benefits, and FDA approval progress, uncertainties remain. The Q&A reveals cautious optimism about regional growth and trial prospects but lacks concrete timelines for France's recovery. The absence of material Virtual Care Suite revenues soon adds to uncertainty. Despite positive restructuring impacts, the lack of immediate revenue growth and specific guidance tempers optimism, suggesting a neutral sentiment.
Allurion Technologies Inc. (ALUR) Q1 2025 Earnings Call Transcript
Positive5-14
The earnings call presents a generally positive outlook with increased gross profit, reduced expenses, and a decrease in operational losses, indicating improved financial health. The Q&A reveals positive momentum in key regions and confidence in FDA approval. Despite some unclear responses, the focus on strategic growth and the potential for increased revenue in the latter half of the year suggest a positive stock price movement. The absence of market cap data limits precise impact prediction, but the overall sentiment leans towards a positive reaction.
ALUR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
